TR200102109T2 - Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. - Google Patents

Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod.

Info

Publication number
TR200102109T2
TR200102109T2 TR2001/02109T TR200102109T TR200102109T2 TR 200102109 T2 TR200102109 T2 TR 200102109T2 TR 2001/02109 T TR2001/02109 T TR 2001/02109T TR 200102109 T TR200102109 T TR 200102109T TR 200102109 T2 TR200102109 T2 TR 200102109T2
Authority
TR
Turkey
Prior art keywords
ras
cyclodextrin
complex
sulfobutylether
hydroxypropyl
Prior art date
Application number
TR2001/02109T
Other languages
English (en)
Inventor
S. Raghavan Krishnaswamy
M. Malloy Timothy
A. Varia Sailesh
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of TR200102109T2 publication Critical patent/TR200102109T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bir ras-farnesiltransferazi inhibitörü kompleksi olup, formül (I)'i havi ras-farnesiltransferazi inhibitörünü veya bunun farmasötik yönden kabul edilebilir bir tuzunu ve sülfobütileter-7- -siklodekstrini veya 2-hidroksipropil- -siklodekstrini ihtiva eder, ve burada n 0 veya 1'dir; R1 C1, Br, fenil, piridil veya siyanodan seçilir; R2 aralkildir; R3 sayica düsük karbonlu alkil, aril, veya ikameli/katkili aril veya heterosiklodan seçilir; Z1 CO, SO2, CO2, SO2NR5 den seçilir ve burada R5 hidrojen, sayica düsük karbonlu alkil veya ikameli/katkili alkilden seçilir. Bu kompleks ras-farnesiltrasferazi inhibitörünün beklenmedik derecede yüksek olan bir suda erime kabiliyetini ortaya koyar ve kansere yakalanmis olan insanlara damar içine uygulanmaya uygundur. Kompleksin meydana getirilmesine yönelik bir metod da ortaya konulmaktadir. Ras-farnesiltransferazi inhibitörleri anti-tümör ajanlar olarak faydalidir.
TR2001/02109T 1999-01-21 1999-12-21 Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. TR200102109T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21

Publications (1)

Publication Number Publication Date
TR200102109T2 true TR200102109T2 (tr) 2001-12-21

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02109T TR200102109T2 (tr) 1999-01-21 1999-12-21 Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod.

Country Status (33)

Country Link
US (1) US6218375B1 (tr)
EP (1) EP1143796A4 (tr)
JP (1) JP2002535253A (tr)
KR (1) KR100708360B1 (tr)
CN (1) CN1219517C (tr)
AR (1) AR022323A1 (tr)
AU (1) AU772204B2 (tr)
BG (1) BG105666A (tr)
BR (1) BR9916566A (tr)
CA (1) CA2359646C (tr)
CO (1) CO5160253A1 (tr)
CZ (1) CZ20012601A3 (tr)
EE (1) EE200100382A (tr)
GE (1) GEP20043214B (tr)
HK (1) HK1038865A1 (tr)
HU (1) HUP0105160A3 (tr)
ID (1) ID30139A (tr)
IL (1) IL144025A (tr)
LT (1) LT4893B (tr)
LV (1) LV12712B (tr)
MY (1) MY119700A (tr)
NO (1) NO20013585L (tr)
NZ (1) NZ511995A (tr)
PE (1) PE20001419A1 (tr)
PL (1) PL195280B1 (tr)
RU (1) RU2230062C2 (tr)
SK (1) SK9602001A3 (tr)
TR (1) TR200102109T2 (tr)
TW (1) TWI232752B (tr)
UA (1) UA67825C2 (tr)
UY (2) UY25986A1 (tr)
WO (1) WO2000042849A1 (tr)
ZA (1) ZA200104416B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
AU2002359412A1 (en) * 2001-11-13 2003-05-26 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040009972A1 (en) * 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
BRPI0616447A2 (pt) * 2005-09-30 2011-06-21 Ovation Pharmaceuticals Inc complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
RU2009123536A (ru) * 2006-11-21 2010-12-27 Новартис АГ (CH) Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина
HUE037716T2 (hu) 2008-10-22 2018-09-28 Array Biopharma Inc Szubsztituált pirazolo[l,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
AU2011258964B2 (en) 2010-05-26 2015-04-16 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
WO2012034038A2 (en) 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
EP2763681B1 (en) * 2011-10-07 2017-08-16 Pisces Therapeutics LLC Malignant and non-malignant disease treatment with ras antagonists
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
AU2016372396B2 (en) 2015-12-16 2022-04-14 Neurophyxia B.V. 2-iminobiotin for use in the treatment of brain cell injury
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
UY25987A1 (es) 2000-09-29
KR20010101611A (ko) 2001-11-14
AR022323A1 (es) 2002-09-04
TWI232752B (en) 2005-05-21
CN1219517C (zh) 2005-09-21
LT2001064A (en) 2001-10-25
JP2002535253A (ja) 2002-10-22
CA2359646A1 (en) 2000-07-27
LV12712A (lv) 2001-09-20
CZ20012601A3 (cs) 2002-05-15
KR100708360B1 (ko) 2007-04-17
PE20001419A1 (es) 2001-02-21
MY119700A (en) 2005-06-30
PL195280B1 (pl) 2007-08-31
GEP20043214B (en) 2004-04-26
EP1143796A4 (en) 2002-03-20
ZA200104416B (en) 2002-05-29
NZ511995A (en) 2003-11-28
IL144025A (en) 2004-05-12
RU2230062C2 (ru) 2004-06-10
IL144025A0 (en) 2002-04-21
UA67825C2 (uk) 2004-07-15
LT4893B (lt) 2002-02-25
EP1143796A1 (en) 2001-10-17
WO2000042849A1 (en) 2000-07-27
BG105666A (en) 2002-04-30
BR9916566A (pt) 2001-11-13
CA2359646C (en) 2008-12-02
SK9602001A3 (en) 2002-06-04
UY25986A1 (es) 2000-09-29
CO5160253A1 (es) 2002-05-30
HUP0105160A2 (hu) 2002-05-29
HUP0105160A3 (en) 2003-01-28
PL366338A1 (en) 2005-01-24
NO20013585D0 (no) 2001-07-20
LV12712B (en) 2002-01-20
CN1333651A (zh) 2002-01-30
NO20013585L (no) 2001-09-04
EE200100382A (et) 2002-12-16
HK1038865A1 (zh) 2002-04-04
ID30139A (id) 2001-11-08
AU772204B2 (en) 2004-04-22
AU2374000A (en) 2000-08-07
US6218375B1 (en) 2001-04-17

Similar Documents

Publication Publication Date Title
TR200102109T2 (tr) Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod.
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
UA41247C2 (uk) Похідні n-фенілпіразолу
HUP0003355A2 (hu) Tieno[2,3-d]pirimidindion-származékok és ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
YU40799A (sh) Pirazinska jedinjenja
NO934792L (no) Xantinderivater
HUP0001046A2 (hu) Ftálazin-származékok angiogenezis-gátló hatással
CA2074853A1 (en) 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
CA2328780A1 (en) Dihydropyrimidines
CA2188690A1 (en) Selective thrombin inhibitors
ES2012646A6 (es) Un procedimiento para la preparacion de derivados de piridazinona.
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
IT1315267B1 (it) Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
BG101601A (en) Pharmaceutical piperazine compounds
BG103735A (en) Method for the preparation of substituted thiazolidindions
NZ334030A (en) Synthesis of bisindolylmalimides
TW350838B (en) Quinoline derivatives
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
KR970702848A (ko) 아릴피페리딘 및 아릴피페라진 유도체 및 이를 함유하는 약제(Arylpiperidine and arylpiperazine derivatives and drugs containing the same)
TW325463B (en) 4-Aminobenzoylguanidine-derivatives
ATE195728T1 (de) Pyridinderivate als hydroxylase- und lyase- inhibitoren